Effect of Sitagliptin on Blood Pressure and Estimated Glomerular Filtration Rate in Diabetic Patients Using an Angiotensin II Receptor Blocker

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Sitagliptin, a dipeptidyl peptidase-IV inhibitor, is widely used as an oral hypoglycemic agent. It may induce hemodynamic effects when interacting with angiotensin II receptor blockers. Methods: The study was conducted in an outpatient setting at Taipei Medical University Hospital. Diabetic patients who had already received angiotensin II receptor blockers for more than 6 months and then had add-on sitagliptin for another 6 months were enrolled. The blood pressures and serum creatinine levels during the 6-month period before and after onset of concomitant use of the two agents were obtained by chart reviewing. Results: Elevation of serum creatinine levels and reduction of estimated glomerular filtration rates were present after the addition of sitagliptin (p <0.05). Moreover, a trend of reduction in diastolic blood pressure was also noted. Patients with chronic kidney disease and coronary artery disease were prone to have decreased diastolic blood pressures after combined use of valsartan and sitagliptin. Patients with chronic kidney disease alone were prone to have elevation of serum creatinine levels after combined treatment of valsartan and sitagliptin. Conclusion: The addition of sitagliptin produced a trend of blood pressure lowering effects and decreased the glomerular filtration rate and HbA1c in diabetic patients using an angiotensin II receptor blocker, especially in those with chronic kidney disease.

Original languageEnglish
Pages (from-to)334-337
Number of pages4
JournalJournal of Experimental and Clinical Medicine(Taiwan)
Volume4
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Angiotensin Receptor Antagonists
Glomerular Filtration Rate
Valsartan
Blood Pressure
Chronic Renal Insufficiency
Creatinine
Serum
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Sitagliptin Phosphate
Coronary Artery Disease
Outpatients
Hemodynamics

Keywords

  • Angiotensin II receptor blockers
  • Blood pressure
  • Dipeptidyl peptidase-IV inhibitors
  • Glomerular filtration rate
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{daefccc6eb744336a216261ea07605a8,
title = "Effect of Sitagliptin on Blood Pressure and Estimated Glomerular Filtration Rate in Diabetic Patients Using an Angiotensin II Receptor Blocker",
abstract = "Background: Sitagliptin, a dipeptidyl peptidase-IV inhibitor, is widely used as an oral hypoglycemic agent. It may induce hemodynamic effects when interacting with angiotensin II receptor blockers. Methods: The study was conducted in an outpatient setting at Taipei Medical University Hospital. Diabetic patients who had already received angiotensin II receptor blockers for more than 6 months and then had add-on sitagliptin for another 6 months were enrolled. The blood pressures and serum creatinine levels during the 6-month period before and after onset of concomitant use of the two agents were obtained by chart reviewing. Results: Elevation of serum creatinine levels and reduction of estimated glomerular filtration rates were present after the addition of sitagliptin (p <0.05). Moreover, a trend of reduction in diastolic blood pressure was also noted. Patients with chronic kidney disease and coronary artery disease were prone to have decreased diastolic blood pressures after combined use of valsartan and sitagliptin. Patients with chronic kidney disease alone were prone to have elevation of serum creatinine levels after combined treatment of valsartan and sitagliptin. Conclusion: The addition of sitagliptin produced a trend of blood pressure lowering effects and decreased the glomerular filtration rate and HbA1c in diabetic patients using an angiotensin II receptor blocker, especially in those with chronic kidney disease.",
keywords = "Angiotensin II receptor blockers, Blood pressure, Dipeptidyl peptidase-IV inhibitors, Glomerular filtration rate, Type 2 diabetes mellitus",
author = "Liu, {Chung Te} and Tso-Hsiao Chen and Hsi-Hsien Chen and Yen-Chung Lin and Tzen-Wen Chen",
year = "2012",
month = "12",
doi = "10.1016/j.jecm.2012.10.001",
language = "English",
volume = "4",
pages = "334--337",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Effect of Sitagliptin on Blood Pressure and Estimated Glomerular Filtration Rate in Diabetic Patients Using an Angiotensin II Receptor Blocker

AU - Liu, Chung Te

AU - Chen, Tso-Hsiao

AU - Chen, Hsi-Hsien

AU - Lin, Yen-Chung

AU - Chen, Tzen-Wen

PY - 2012/12

Y1 - 2012/12

N2 - Background: Sitagliptin, a dipeptidyl peptidase-IV inhibitor, is widely used as an oral hypoglycemic agent. It may induce hemodynamic effects when interacting with angiotensin II receptor blockers. Methods: The study was conducted in an outpatient setting at Taipei Medical University Hospital. Diabetic patients who had already received angiotensin II receptor blockers for more than 6 months and then had add-on sitagliptin for another 6 months were enrolled. The blood pressures and serum creatinine levels during the 6-month period before and after onset of concomitant use of the two agents were obtained by chart reviewing. Results: Elevation of serum creatinine levels and reduction of estimated glomerular filtration rates were present after the addition of sitagliptin (p <0.05). Moreover, a trend of reduction in diastolic blood pressure was also noted. Patients with chronic kidney disease and coronary artery disease were prone to have decreased diastolic blood pressures after combined use of valsartan and sitagliptin. Patients with chronic kidney disease alone were prone to have elevation of serum creatinine levels after combined treatment of valsartan and sitagliptin. Conclusion: The addition of sitagliptin produced a trend of blood pressure lowering effects and decreased the glomerular filtration rate and HbA1c in diabetic patients using an angiotensin II receptor blocker, especially in those with chronic kidney disease.

AB - Background: Sitagliptin, a dipeptidyl peptidase-IV inhibitor, is widely used as an oral hypoglycemic agent. It may induce hemodynamic effects when interacting with angiotensin II receptor blockers. Methods: The study was conducted in an outpatient setting at Taipei Medical University Hospital. Diabetic patients who had already received angiotensin II receptor blockers for more than 6 months and then had add-on sitagliptin for another 6 months were enrolled. The blood pressures and serum creatinine levels during the 6-month period before and after onset of concomitant use of the two agents were obtained by chart reviewing. Results: Elevation of serum creatinine levels and reduction of estimated glomerular filtration rates were present after the addition of sitagliptin (p <0.05). Moreover, a trend of reduction in diastolic blood pressure was also noted. Patients with chronic kidney disease and coronary artery disease were prone to have decreased diastolic blood pressures after combined use of valsartan and sitagliptin. Patients with chronic kidney disease alone were prone to have elevation of serum creatinine levels after combined treatment of valsartan and sitagliptin. Conclusion: The addition of sitagliptin produced a trend of blood pressure lowering effects and decreased the glomerular filtration rate and HbA1c in diabetic patients using an angiotensin II receptor blocker, especially in those with chronic kidney disease.

KW - Angiotensin II receptor blockers

KW - Blood pressure

KW - Dipeptidyl peptidase-IV inhibitors

KW - Glomerular filtration rate

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84871440827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871440827&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2012.10.001

DO - 10.1016/j.jecm.2012.10.001

M3 - Article

AN - SCOPUS:84871440827

VL - 4

SP - 334

EP - 337

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 6

ER -